LifeMD, Inc. (NASDAQ:LFMDP) Short Interest Down 33.3% in February

LifeMD, Inc. (NASDAQ:LFMDP) was the target of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 200 shares, a decline of 33.3% from the January 31st total of 300 shares. Based on an average trading volume of 2,000 shares, the days-to-cover ratio is presently 0.1 days.

LifeMD Stock Down 0.1 %

LFMDP stock traded down $0.03 during trading on Tuesday, reaching $22.85. 3,149 shares of the stock were exchanged, compared to its average volume of 2,459. LifeMD has a twelve month low of $20.00 and a twelve month high of $25.00. The stock has a 50 day simple moving average of $22.42 and a 200-day simple moving average of $22.33.

LifeMD Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, January 3rd were given a $0.5547 dividend. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.22 annualized dividend and a yield of 9.71%.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.